Allied Market Research published a report, titled, “Bispecific Antibody Market by Product (Blinatumomab, Emicizumab, and Others), Application (Cancer, Hemophilia, and Others) and End User (Hospitals, Cancer Center and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032”. According to the report, the global bispecific antibody market was valued at $5.5 billion in 2022, and is projected to reach $109.4 billion by 2032, registering a CAGR of 34.8% from 2023 to 2032.
Market Dynamics
The bispecific antibody is an artificially developed antibody having the ability to bind to two different antigens or epitopes. These antibodies have numerous applications in healthcare sectors such as in oncology and treatment of infectious diseases and autoimmune diseases. Their revolutionary applications and versatility have made them a crucial component of R&D processes in the pharmaceutical and biomedical industries.
Bispecific antibodies are artificial proteins that have promising applications in the field of cancer and immunotherapy. They are comprised of two monoclonal antibodies which are held together by a flexible peptide linker. This makes them able to bind to two different antigens, as the name suggests. The unique properties of bispecific antibodies make them versatile therapeutic agents. They improve therapy effectiveness, target certain cell types, and address complex disease pathways. Bispecific antibodies act as a bridge between cancer cells and cytotoxic T lymphocytes (CTLs). They bind CD3 antigens on CTLs and a specific antigen on cancer cells, which in turn activates the T cells, promotes the lysis of cancer cells, and make bispecific antibody effective in cancer treatment.
Request Sample of the Report: https://www.alliedmarketresearch.com/request-sample/130431
Segmental Overview
On the basis of product, the bispecific antibody market size is classified into blinatumomab, emicizumab, and others. Others includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. The blinatumomab segment is expected to be the fastest-growing segment during the forecast period owing to the increase in incidences of leukemia and rise in technological advances in the field of cancer treatments.
On the basis of application, the bispecific antibody market analysis is classified into cancer, hemophilia, and others. Others includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. The hemophilia segment is projected to be the fastest growing segment during the forecast period, owing to a rise in the number of populations suffering from hemophilia and increase in the awareness among the people regarding treatment of hemophilia.
On the basis of end user, the bispecific antibody market share is classified into hospitals, cancer centers, and others. The hospitals segment is projected to be the fastest growing segment during the forecast period owing to rise in the number of initiatives taken by government for development of healthcare infrastructure and rise in the prevalence of chronic diseases and autoimmune diseases.
On the basis of region, North America had the highest bispecific antibody market share in 2022 and is expected to maintain its lead during the forecast period owing to increase in prevalence of cancer, growth in demand for next-generation antibody therapeutics, and technological advancement in the healthcare sector. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to the fact that this region has large and growing population, which is susceptible to the rise in prevalence of infectious diseases, rise in the number of product approvals for bispecific antibodies and increase in the strategic partnership among the market players.
Leading Market Players
The report provides a detailed analysis of these key players of the global bispecific antibody market. These players have adopted different strategies such as agreement, partnership, acquisition, and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bispecific antibody market analysis from 2022 to 2032 to identify the prevailing bispecific antibody market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the bispecific antibody market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global bispecific antibodies market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the bispecific antibody market players.
- The report includes the analysis of the regional as well as global bispecific antibodies market trends, key players, market segments, application areas, and market growth strategies.
Read More:
Hearing Aid Market Worth USD 15.1 billion Milestone by 2033 At a CAGR of 6.6%
Immunology Market to Reach $204.0 Billion by 2033, Driven by 6.3% CAGR From 2024-2033
Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
